NASDAQ$VCEL
Vericel Corporation · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported a strong financial performance with significant revenue growth and improved profitability.
Vericel Corporation reported a significant increase in revenue for the second quarter of 2021, with total net revenue increasing by 97% to $39.5 million. The company also raised its full-year 2021 revenue guidance to $168-$171 million. Net loss decreased to $3.8 million, or $0.08 per share, and non-GAAP adjusted EBITDA was $7.8 million, or 20% of net revenue.
- Total net revenue increased by 97% to $39.5 million compared to Q2 2020.
- MACI net revenue grew by 76% compared to the second quarter of 2020.
- Epicel net revenue increased by 148% compared to the second quarter of 2020, achieving a record quarterly high.
- Full-year 2021 revenue guidance was raised to $168-$171 million.
Headline financials
Revenue & EPS history
Vericel · Revenue · Quarterly
$39.5M
Revenue by segment
Vericel · $39.5M total across 3 segments · Q2 2021
- MACI$26.5M+75.5%67.1%
- Epicel$12.2M+149.0%30.9%
- NexoBrid$800K—2.0%
Forward guidance
Vericel expects total net revenue to be in the range of $168-$171 million and adjusted EBITDA margin to be in the range of 23% to 25%. They are maintaining gross margin guidance of 70% to 71% and estimated operating expenses of approximately $115 million.
Tailwinds
- Total net revenue now expected to be in the range of $168-$171 million, compared to previous guidance of approximately $165-$168 million
- Adjusted EBITDA margin now expected to be in the range of 23% to 25%, compared to previous guidance of 21.5% to 23.5%
- Maintaining gross margin guidance of 70% to 71%
- The Company continued to execute extremely well in the second quarter
- The Company is well-positioned to continue driving sustainable penetration into the addressable markets for both products in the years ahead
Headwinds
- Estimated operating expenses of approximately $115 million
- Uncertainties associated with expectations regarding future revenue
- Potential fluctuations in sales and volumes and our results of operations over the course of the year
- Wide-ranging impacts of the COVID-19 pandemic on our business or the economy generally
- The COVID-19 pandemic may impact the FDA’s response times to future regulatory submissions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+2.2%
Avg return
30 days after
47%
30 / 64 earnings
Positive
+48.1%
Q3 2018
Best reaction
-30.0%
Q2 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -10.4% | -1.4% | |
| Q4 2025 | +1.7% | -7.3% | -20.9% | |
| Q3 2025 | +4.6% | +10.3% | -2.6% | |
| Q1 2025 | +3.2% | +7.8% | +7.0% | |
| Q4 2024 | -6.1% | -3.2% | -15.8% | |
| Q3 2024 | +12.4% | +16.3% | +17.3% | |
| Q2 2024 | -5.7% | -7.5% | +2.2% | |
| Q1 2024 | -1.8% | -2.0% | -10.4% | |
| Q4 2023 | -6.5% | -7.0% | +8.8% | |
| Q3 2023 | -11.2% | -7.0% | -7.3% | |
| Q2 2023 | -8.9% | -9.2% | -3.5% | |
| Q1 2023 | +0.5% | +2.8% | +6.5% | |
| Q4 2022 | +6.9% | +6.6% | +1.6% | |
| Q3 2022 | -2.8% | +0.2% | -0.3% | |
| Q2 2022 | -4.3% | -6.2% | -28.7% | |
| Q1 2022 | -9.1% | -18.9% | -13.1% | |
| Q4 2021 | +21.9% | +26.4% | +11.2% | |
| Q3 2021 | -2.7% | -3.0% | -10.6% | |
| Q2 2021 | -2.1% | -4.5% | +9.0% | |
| Q1 2021 | -10.2% | -15.9% | -5.8% | |
| Q4 2020 | +0.4% | +1.7% | +9.0% | |
| Q3 2020 | +6.0% | +17.7% | +18.5% | |
| Q2 2020 | -9.8% | -5.0% | -5.5% | |
| Q1 2020 | +5.6% | +8.3% | +3.9% | |
| Q4 2019 | -20.4% | -18.3% | -46.9% | |
| Q3 2019 | +15.3% | +15.7% | +12.9% | |
| Q2 2019 | +2.4% | +1.9% | -8.3% | |
| Q1 2019 | -2.5% | -3.6% | -16.8% | |
| Q4 2018 | -7.4% | -3.5% | -13.6% | |
| Q3 2018 | +48.1% | +39.6% | +53.3% | |
| Q2 2018 | +25.6% | +27.1% | +36.5% | |
| Q1 2018 | +6.0% | +5.6% | +0.4% | |
| Q4 2017 | +40.1% | +38.3% | +33.5% | |
| Q3 2017 | -7.0% | -5.8% | +14.0% | |
| Q2 2017 | +11.7% | +21.7% | +48.3% | |
| Q1 2017 | +0.0% | +3.9% | +5.9% | |
| Q4 2016 | -1.7% | +0.0% | -6.9% | |
| Q3 2016 | -2.3% | +4.7% | +9.3% | |
| Q2 2016 | -5.5% | -7.7% | -5.5% | |
| Q1 2016 | +11.5% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -9.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +2.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q2 2014 | -0.3% | — | — | |
| Q1 2014 | +0.5% | — | — | |
| Q4 2013 | -12.7% | — | — | |
| Q3 2013 | -2.2% | — | — | |
| Q2 2013 | -30.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -6.3% | — | — | |
| Q3 2012 | -4.0% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | +3.1% | — | — | |
| Q2 2011 | +8.3% | — | — | |
| Q1 2011 | +4.7% | — | — | |
| Q4 2009 | +4.7% | — | — | |
| Q3 2010 | +35.3% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro